Ellipses Pharma explores the need and potential for next generation SRIs as well as the global need to keep improving the clinical trial structure and landscape
Phesi considers patient enrolment and retention in clinical trials, with a focus on oncology trials and the challenges facing them
Gilead Sciences considers the current treatments available for blood cancers as well as how these are likely to develop in the future
Charac considers the NHS’s new Pharmacy First scheme, the benefits of the scheme and barriers to its implementation
Cognitant Group explores the need for patient support programmes, and how these can be improved
Pharmafocus considers the current rise of measles cases in the UK and the measures that should be taken to prevent further infections
Page 5 – FDA accepts argenx’ sBLA for Vyvgart Hytrulo for CIDP treatment
Page 7 – ViiV Healthcare announces interim results from phase 3 trial for HIV treatment
Page 9 – AbbVie’s Tepkinly recommended by NICE for SC treatment of DLBCL
Page 11 – BioNTech and Autolus collaborate for CAR T-cell therapies

Our Team

Executive Director
PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
Editorial Assistants
Betsy Goodfellow
Sales Manager
Eliot Haynes
Design & Layout
Peter May
Pharmafocus is published by:
Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
ISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2024 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.